Importantly, inhibition of necroptosis with necrostatin-1 and knockdown of MLKL expression successfully prevented cells from undergoing necroptosis-induced cell death, suggesting that targeting necroptotic pathways could be a noteworthy therapeutic strategy in inflammatory myopathy treatment [95]. This evidence concerns the gene MLKL and myopathy.